Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
September 16 2008 - 8:00AM
PR Newswire (US)
SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Ardea Biosciences,
Inc. (NASDAQ:RDEA) announced today that the Company will present
preclinical data on RDEA594, its lead product candidate for the
treatment of gout, as well as preclinical data on RDEA119,its lead
mitogen-activated ERK kinase (MEK) inhibitor for the treatment of
inflammation associated with gouty arthritis, at the 2008 American
College of American College of Rheumatology (ACR) / Association of
Rheumatology Health Professionals (ARHP) Annual Scientific Meeting
in San Francisco, California. Presentation Details are as Follows:
Date/Time: Sunday, October 26, 2008, 9:00 a.m. - 11:00 a.m. PDT
Abstract Title: RDEA594, A Potential Uric Acid Lowering Agent
through Inhibition of Uric Acid Reuptake, Shows Better
Pharmakokinetics than its Prodrug RDEA806 Abstract Number: 28
Session Name: Crystal Associated Arthropathies Location: Hall A,
Poster Board 28 Date/Time: Tuesday, October 28, 2008, 2:45 p.m. -
3:00 p.m. PDT Abstract Title: MEK Inhibitor RDEA119 Suppresses
Inflammatory Cytokine Production Induced by Monosodium Urate
Crystals Abstract Number: 1942 Session Name: Crystal Associated
Arthropathies Location: Room 104 About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a
biotechnology company focused on the discovery and development of
small-molecule therapeutics for the treatment of HIV, gout, cancer
and inflammatory diseases. We have five product candidates in
clinical trials and others in preclinical development and
discovery. Our most advanced product candidate is RDEA806, a
non-nucleoside reverse transcriptase inhibitor (NNRTI), which has
successfully completed a Phase 2a study for the treatment of
patients with HIV. We have evaluated our second-generation NNRTI
for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development. RDEA594, our lead product candidate for the treatment
of gout, is being evaluated in a Phase 1 clinical trial and is
believed to be an inhibitor of the URAT1 transporter in the kidney,
which is responsible for regulation of uric acid levels. We are
evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in
advanced cancer patients, and have completed a Phase 1 study in
normal healthy volunteers as a precursor to trials in patients with
inflammatory diseases. Lastly, we have evaluated our
second-generation MEK inhibitor for the treatment of cancer and
inflammatory diseases, RDEA436, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development. Statements contained in this press release regarding
matters that are not historical facts are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds
and the results of preclinical, clinical and other studies. Risks
that contribute to the uncertain nature of the forward- looking
statements include: risks related to the outcome of preclinical and
clinical studies, risks related to regulatory approvals, delays in
commencement of preclinical and clinical studies, and costs
associated with our drug discovery and development programs and
business development activities. These and other risks and
uncertainties are described more fully in our most recently filed
SEC documents, including our Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q, under the headings "Risk Factors."
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.
DATASOURCE: Ardea Biosciences, Inc. CONTACT: Investors, John Beck
of Ardea Biosciences, +1-858-652-6523, ; or Media, Edie DeVine of
WeissComm Partners, +1-415-946-1081, , for Ardea Biosciences, Inc.
Copyright
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jul 2023 to Jul 2024